Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

“It took us a century to reach 40 million patients, but through this expansion and continued investment in our global production, we’re building Novo Nordisk’s ability to serve millions more ...

(Bloomberg) -- Novo Nordisk A/S has a successor waiting in the ... like Eli Lilly & Co., Amgen Inc. and Pfizer Inc. Chief Executive Officer Lars Fruergaard Jorgensen acknowledges that Novo ...

Others that are positioned to compete with Novo Nordisk in the weight loss market include Amgen, Zealand Pharma, and more recently, Merck & Co Inc. The announcement is significant for Novo Nordisk ...

Danish pharma Novo Nordisk posted second-quarter operating profit in line with forecasts but hinted about the possibility of cutting the price of some drugs on the US market next year. The world ...

Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new trial, adding to growing threats to the Danish company’s early ...

Novo Nordisk NOVO.B9.60%increase; green up pointing triangle shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot showed patients lost 22% of their ...

Pfizer’s top-selling breast cancer drug Ibrance also on list Drugmakers plan to ask Trump administration to pause talks The ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...